Xiaofang Hu

机构：Hebei Medical University, Nanjing University of Chinese Medicine, Hunan Normal University, Shenzhen University, Quzhou City People's Hospital, ShenZhen People’s Hospital, University of Hong Kong - Shenzhen Hospital, Shenzhen Nanshan Center for Chronic Disease Control · ORCID：0000-0001-7766-4639

发表论文 47 篇 · 总被引 935 次 · h-index 18

代表论文

• Characterizing the gut microbiota in patients with chronic kidney disease (2020 · Postgraduate Medicine · 被引 107)
• Fecal microbiota characteristics of Chinese patients with primary IgA nephropathy: a cross-sectional study (2020 · BMC Nephrology · 被引 92)
• The protective role of DPP4 inhibitors in atherosclerosis (2020 · European Journal of Pharmacology · 被引 52)
• Role of the CTRP6/AMPK pathway in kidney fibrosis through the promotion of fatty acid oxidation (2020 · European Journal of Pharmacology · 被引 32)
• IGFBP5 promotes EndoMT and renal fibrosis through H3K18 lactylation in diabetic nephropathy (2025 · Cellular and Molecular Life Sciences · 被引 27)
• Longitudinal analysis of fecal microbiome and metabolome during renal fibrotic progression in a unilateral ureteral obstruction animal model (2020 · European Journal of Pharmacology · 被引 26)